Cargando…

Early Start of Infliximab in Crohn’s Disease Increases Rates of Endoscopic Remission and Decreases Stenosis Formation: Experiences From a Single Center Cohort

BACKGROUND: Over 10 years ago, the step-up/top-down trial demonstrated favorable outcomes of Crohn’s disease (CD) after early initiation of infliximab (IFX) in patients with CD. However, data on long-term effects of this treatment strategy in daily clinical practice are scarce. METHODS: This retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnitzler, Fabian, Seitz, Theresia, Tillack-Schreiber, Cornelia, Lange, Silke, Waggershauser, Constanze, Ochsenkühn, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802408/ https://www.ncbi.nlm.nih.gov/pubmed/36776655 http://dx.doi.org/10.1093/crocol/otab060

Ejemplares similares

Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients
por: Waggershauser, Constanze Heike, et al.
Publicado: (2022)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index
por: Walshe, Margaret, et al.
Publicado: (2021)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease
por: Sollelis, Elisa, et al.
Publicado: (2019)

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China
por: Shi, Ji-Hao, et al.
Publicado: (2020)

Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease
por: Thomassin, Lucie, et al.
Publicado: (2017)

A Novel Capsule Endoscopic Score for Crohn’s Disease
por: Omori, Teppei, et al.
Publicado: (2020)

The Impact of Confounders on Symptom–Endoscopic Discordances in Crohn’s Disease
por: Rajan, Anjana, et al.
Publicado: (2023)

The Effect of Early vs Delayed Initiation of Adalimumab on Remission Rates in Patients With Crohn’s Disease With Poor Prognostic Factors: The MODIFY Study
por: Mantzaris, Gerassimos J, et al.
Publicado: (2021)

Histologic Inflammation can Predict Future Clinical Relapse in Ulcerative Colitis Patients in Endoscopic Remission
por: George, Lauren A, et al.
Publicado: (2023)

Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study
por: Sirmai, Laura, et al.
Publicado: (2022)

Faecal calprotectin and magnetic resonance imaging in detecting Crohn’s disease endoscopic postoperative recurrence
por: Baillet, Pierre, et al.
Publicado: (2018)

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States
por: Smith, Joshua T, et al.
Publicado: (2021)

Discontinuation of Scheduled Infliximab in Crohn’s Patients With Clinical Remission: A Retrospective Single-Center Study
por: Hu, Huiqin, et al.
Publicado: (2017)

Patient’s Perspective on Disease Burden, Remission Definition, and Symptoms Associated With Treatment Seeking: A Qualitative Study in Adult and Adolescent Patients With Crohn’s Disease
por: Kitchen, Helen, et al.
Publicado: (2020)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring
por: Hemperly, Amy, et al.
Publicado: (2021)

Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn’s disease and active smoking status resulting in ileal stenosis requiring surgery
por: Schnitzler, Fabian, et al.
Publicado: (2020)

Outcomes of Pediatric Patients with Crohn's Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission
por: Lv, Yao, et al.
Publicado: (2022)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Remission of generalized erythematous granuloma annulare after improvement of hyperlipidemia and review of the Japanese literature
por: Watanabe, Soko, et al.
Publicado: (2014)

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Body composition parameters correlate with the endoscopic severity in Crohn’s disease patients treated with infliximab
por: Tang, Wuli, et al.
Publicado: (2023)

Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab
por: Minar, Phillip, et al.
Publicado: (2019)

Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction
por: Normatov, Inessa, et al.
Publicado: (2021)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Congenital intrarenal arteriovenous malformation presenting with gross hematuria after endoscopic intervention: a case report
por: Seitz, Michael, et al.
Publicado: (2008)

Efficacy and outcomes of endoscopic management of post-tracheostomy tracheal stenosis: a retrospective study from an interventional center in China
por: Chen, Feng, et al.
Publicado: (2022)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

An itchy rash in a young Caucasian woman
por: Jonak, Constanze, et al.
Publicado: (2012)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Ideal Vial Size for Infliximab in the Treatment of Inflammatory Bowel Disease: An Analysis of Pharmaceutical Waste and Physician Opinions
por: Schachne, Jonathan M, et al.
Publicado: (2021)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
por: Hirayama, Hisashi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ql6h58dcasdde69jvg5dk7ecim